Renishaw Diagnostics Ltd, developers of the RenDx™ Multiplex Assay System for infectious disease research and diagnosis, today announced that it has been certified to ISO 13485:2003 for the following scope: design, development, product manufacture and management of subcontracted manufacture of molecular diagnostic systems for infectious diseases.
Renishaw Diagnostics Ltd, the developers of the RenDx™ Multiplex Assay System for infectious disease research and diagnosis today announced that it has created another 8 jobs; almost a 30% increase on its current workforce. The company also announced that its diagnostics project leader, Dr Karen Fitchett, has passed the Lean Six Sigma Green Belt exam of the British Quality Foundation certification, one of the most prestigious management qualifications.
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS) for infectious disease research and molecular diagnostics applications, today announced that it has established a contract reagent manufacturing agreement with Gen-Probe’s Cardiff facility.
Renishaw Diagnostics Ltd, today announced that it has concluded an exclusive licence agreement to a patent on nucleic acid sequence identification (SERRS beacons) from The University of Strathclyde.
Renishaw Diagnostics Ltd (formerly D3 Technologies), a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS), for research and molecular diagnostics applications, today announced details of a talk to be presented at PittCon 2011 in Atlanta, Georgia later this month.
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS), for research and molecular diagnostics applications, today announced the launch of its first research use only (RUO) multiplex assay system which allows precious research samples to be ‘screened’ for 10 or more ‘targets’, from a single sample.
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced resonance Raman scattering (SERRS), for life science research and molecular diagnostics applications, today announced its intention to create another 7 new jobs immediately: almost a 30% increase on its current workforce.
Renishaw Diagnostics Ltd today held its official opening of expanded premises on the Nova Technology Park. The company first moved into 3000sq.ft. custom-built laboratory and office space on the technology park in December 2007. Renishaw Diagnostic’s success in molecular diagnostics development with its clinical research collaborators coupled with its comprehensive business strategy required expanded facilities for an increased number of research and commercial staff.
Renishaw Diagnostics Ltd today announced that it has appointed Jim Greaves as Head of Marketing. He will help prepare the organisation for the international launch of its first in-vitro diagnostic (IVD) products, with the aim to establish Renishaw Diagnostics as a global player in the field of molecular diagnostics for human infectious diseases.
D3 Technologies Ltd today announced that it has changed its name to Renishaw Diagnostics Ltd. David A. Burns, CEO, said "the change of name to Renishaw Diagnostics reflects the direct focus of the Company to become the premier provider of automated multiplex diagnostic and clinical research systems. These patented technology based systems will enable our customers to carry out fast, reliable and simplified disease detection leading to improved patient care."
Renishaw Diagnostics Ltd, developers of the RenDx™ Multiplex Assay System for infectious disease research and diagnosis, today announced that it has been certified to ISO 13485:2003 for the following scope: design, development, product manufacture and management of subcontracted manufacture of molecular diagnostic systems for infectious diseases.
Renishaw Diagnostics Ltd, the developers of the RenDx™ Multiplex Assay System for infectious disease research and diagnosis today announced that it has created another 8 jobs; almost a 30% increase on its current workforce. The company also announced that its diagnostics project leader, Dr Karen Fitchett, has passed the Lean Six Sigma Green Belt exam of the British Quality Foundation certification, one of the most prestigious management qualifications.
Renishaw Diagnostics Ltd (formerly D3 Technologies), a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS), for research and molecular diagnostics applications, today announced details of a talk to be presented at PittCon 2011 in Atlanta, Georgia later this month.
Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering (SERS) and surface enhanced resonance Raman scattering (SERRS), for research and molecular diagnostics applications, today announced the launch of its first research use only (RUO) multiplex assay system which allows precious research samples to be ‘screened’ for 10 or more ‘targets’, from a single sample.
Renishaw Diagnostics Ltd today held its official opening of expanded premises on the Nova Technology Park. The company first moved into 3000sq.ft. custom-built laboratory and office space on the technology park in December 2007. Renishaw Diagnostic’s success in molecular diagnostics development with its clinical research collaborators coupled with its comprehensive business strategy required expanded facilities for an increased number of research and commercial staff.
Renishaw Diagnostics Ltd today announced that it has appointed Jim Greaves as Head of Marketing. He will help prepare the organisation for the international launch of its first in-vitro diagnostic (IVD) products, with the aim to establish Renishaw Diagnostics as a global player in the field of molecular diagnostics for human infectious diseases.